Sergey A Boytsov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/956427/publications.pdf

Version: 2024-02-01

203 5,296 27 67
papers citations h-index g-index

233 233 6113
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.	27.0	1,485
2	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61.	1.6	552
3	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation, 2020, 141, 352-361.	1.6	335
4	THE PREVALENCE OF NON-INFECTIOUS DISEASES RISK FACTORS IN RUSSIAN POPULATION IN 2012-2013 YEARS. THE RESULTS OF ECVD-RF. Cardiovascular Therapy and Prevention (Russian Federation), 2014, 13, 4-11.	1.4	154
5	Gut microbiota and diet in patients with different glucose tolerance. Endocrine Connections, 2016, 5, 1-9.	1.9	148
6	Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 5-66.	1.4	126
7	Association between the gut microbiota and diet: Fetal life, early childhood, and further life. Nutrition, 2016, 32, 620-627.	2.4	119
8	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962.	3.9	117
9	Geographic variations in the PARADIGM-HF heart failure trial. European Heart Journal, 2016, 37, 3167-3174.	2.2	114
10	Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. Lancet, The, 2018, 391, 2019-2027.	13.7	96
11	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 2015, 36, 434-439.	2.2	80
12	Consensus of Russian experts on the evaluation of arterial stiffness in clinical practice. Cardiovascular Therapy and Prevention (Russian Federation), 2016, 15, 4-19.	1.4	56
13	HYPERURICEMIA AND ITS CORRELATES IN THE RUSSIAN POPULATION (RESULTS OF ESSE-RF EPIDEMIOLOGICAL)	TjETQq1 I	1 0.78431 <mark>4</mark> 1
14	Know Your Heart: Rationale, design and conduct of a cross-sectional study of cardiovascular structure, function and risk factors in 4500 men and women aged 35-69 years from two Russian cities, 2015-18. Wellcome Open Research, 2018, 3, 67.	1.8	40
15	TWENTY YEARS TRENDS OF OBESITY AND ARTERIAL HYPERTENSION AND THEIR ASSOCIATION IN RUSSIA. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 4-10.	1.4	40
16	Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of) Tj ETQq0 0	OrgBT /Ov	rerlock 10 Tf
17	Association of Insulin Resistance, Arterial Stiffness and Telomere Length in Adults Free of Cardiovascular Diseases. PLoS ONE, 2015, 10, e0136676.	2.5	37
18	SOCIO-ECONOMIC EFFECTIVENESS OF HEALTH SCREENING ACTIVITY IN 2013 IN RUSSIAN FEDERATION. Cardiovascular Therapy and Prevention (Russian Federation), 2014, 13, 4-10.	1.4	37

#	Article	IF	CITATIONS
19	The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. PLoS ONE, 2017, 12, e0181148.	2.5	33
20	Overweight and Obesity in the Russian Population: Prevalence in Adults and Association with Socioeconomic Parameters and Cardiovascular Risk Factors. Obesity Facts, 2019, 12, 103-114.	3.4	31
21	The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia. Genes, 2021, 12, 66.	2.4	31
22	DIAGNOSTICS, TREATMENT, ASSOCIATED CARDIOVASCULAR AND CONCOMITANT NON-CARDIAC DISEASES IN PATIENTS WITH DIAGNOSIS OF "ATRIAL FIBRILLATION―IN REAL OUTPATIENT PRACTICE (ACCORDING TO DA	ιτĄ) Ţj ETC	2q000 o rgBT
23	10, 366-377. Exploring In-hospital Death from Myocardial Infarction in Eastern Europe: From the International Registry of Acute Coronary Syndromes in Transitional Countries (ISACS-TC); on the Behalf of the Working Group on Coronary Pathophysiology & Dictionary Microcirculation of the European Society of Cardiology, Current Vascular Pharmacology, 2014, 12, 903-909.	1.7	30
24	DISTRIBUTION OF LIPID PROFILE VALUES IN ECONOMICALLY ACTIVE MEN AND WOMEN IN RUSSIAN FEDERATION: RESULTS OF THE ESSE-RF STUDY FOR THE YEARS 2012-2014. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 62-67.	1.4	29
25	Metabolically healthy obese and metabolically unhealthy non-obese phenotypes in a Russian population. European Journal of Epidemiology, 2017, 32, 251-254.	5.7	28
26	Cardiac arrhythmias and sudden unexpected death in epilepsy: Results of long-term monitoring. Heart Rhythm, 2021, 18, 221-228.	0.7	27
27	AWARENESS AND TREATMENT SPECIFICS OF STATIN THERAPY IN PERSONS WITH VARIOUS CARDIOVASULAR RISK: THE STUDY ESSE-RF. Cardiovascular Therapy and Prevention (Russian Federation), 2016, 15, 29-37.	1.4	27
28	Noncompaction cardiomyopathy is caused by a novel inâ€frame desmin (DES) deletion mutation within the 1A coiledâ€coil rod segment leading to a severe filament assembly defect. Human Mutation, 2019, 40, 734-741.	2.5	26
29	The Desmin (DES) Mutation p.A337P Is Associated with Left-Ventricular Non-Compaction Cardiomyopathy. Genes, 2021, 12, 121.	2.4	26
30	Global Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007901.	3.9	25
31	Age-Related Left Ventricular Changes and Their Association with Leukocyte Telomere Length in Healthy People. PLoS ONE, 2015, 10, e0135883.	2.5	24
32	What factors do influence arterial hypertension control in Russia. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 53-60.	1.4	24
33	Modern medical treatment with or without carotid endarterectomy for severe asymptomatic carotid atherosclerosis. Journal of Vascular Surgery, 2015, 62, 914-922.	1.1	23
34	COMPARISON OF CORONARY HEART DISEASE MORTALITY IN MEN AND WOMEN AGE 50 YEARS AND OLDER IN RUSSIA AND USA. Russian Journal of Cardiology, 2017, , 100-107.	1.4	21
35	Perspectives: Rationale and design of the ISACS-TC (International Survey of Acute Coronary Syndromes) Tj ETQq1	l 1.0.7843 0.1	814 rgBT /Ove
36	Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia. PLoS ONE, 2016, 11, e0158964.	2.5	20

#	Article	IF	CITATIONS
37	Growth Hormone, Insulin-Like Growth Factor-1, Insulin Resistance, and Leukocyte Telomere Length as Determinants of Arterial Aging in Subjects Free of Cardiovascular Diseases. Frontiers in Genetics, 2017, 8, 198.	2.3	19
38	Increase in perfused boundary region of endothelial glycocalyx is associated with higher prevalence of ischemic heart disease and lesions of microcirculation and vascular wall. Microcirculation, 2018, 25, e12454.	1.8	19
39	Hemi- and Homozygous Loss-of-Function Mutations in DSG2 (Desmoglein-2) Cause Recessive Arrhythmogenic Cardiomyopathy with an Early Onset. International Journal of Molecular Sciences, 2021, 22, 3786.	4.1	19
40	Hospital register of patients with acute cerebrovascular accident (REGION): characteristics of patient and outcomes of hospital treatment. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 32-38.	1.4	19
41	Atorvastatin Therapy Modulates Telomerase Activity in Patients Free of Atherosclerotic Cardiovascular Diseases. Frontiers in Pharmacology, 2016, 7, 347.	3.5	18
42	Comparison of Russian regions by standardized mortality rates from all causes and circulatory system diseases in 2006-2016. Profilakticheskaya Meditsina, 2018, 21, 4.	0.6	18
43	Ambulatory blood pressure and arterial stiffness webâ€based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive) Tj ETQq1 1 (0. 7.8 4314	rgBT/Overlo
44	Ultrasound Markers that Describe Plaques Are More Sensitive than Mean Intima-Media Thickness in Patients with Familial Hypercholesterolemia. Ultrasound in Medicine and Biology, 2012, 38, 417-422.	1.5	16
45	COMORBIDITIES OF ISCHEMIC HEART DISEASE WITH OTHER NON-COMMUNICABLE DISEASES IN ADULT POPULATION: AGE AND RISK FACTORS ASSOCIATION. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1	11047843	1 46 gBT /Cve
46	SOCIAL AND ECONOMIC GRADIENTS OF BEHAVIORAL RISK FACTORS IN RUSSIAN POPULATION (BY THE) T $_{ m J}$ ETQ $_{ m Q}$	0 0 0 rgB1 1.4	「 Overlock] 16
47	<i>Russia SimSmoke</i> : the long-term effects of tobacco control policies on smoking prevalence and smoking-attributable deaths in Russia. Tobacco Control, 2014, 23, 484-490.	3.2	14
48	THE STUDY "REGISTER OF PATIENTS AFTER ACUTE STROKE (REGION)." Part 1. Hospital Prospective Register of Patients after Acute Stroke (According to the Results of the Pilot Phase of the Study). Rational Pharmacotherapy in Cardiology, 2016, 12, 645-653.	0.8	14
49	The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. Journal of Personalized Medicine, 2021, 11, 464.	2.5	14
50	LIFE QUALITY OF PERSONS WITH ARTERIAL HYPERTENSION IN RUSSIA — IS THERE RELATION TO TREATMENT? (BY DATA FROM POPULATIONAL STUDY ESSE-RF). Russian Journal of Cardiology, 2016, , 7-13.	1.4	14
51	EFFICIENCY OF INFLUENZA VACCINATION IN PATIENTS WITH CIRCULATORY SYSTEM DISEASES UNDER DISPENSARY OBSERVATION IN OUTPATIENT CLINICS: PROSPECTIVE FOLLOW-UP MONITORING DATA. Rational Pharmacotherapy in Cardiology, 2016, 12, 703-710.	0.8	13
52	Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II). Cardiovascular Diabetology, 2017, 16, 158.	6.8	13
53	Effects of tobacco control policy on cardiovascular morbidity and mortality in Russia. European Journal of Public Health, 2018, 28, 14-16.	0.3	13
54	DES GENE MUTATION IN A FAMILY OF PROBAND WITH MYOFIBRILLARY MYOPATHY AND NON-COMPACTION CARDIOMYOPATHY, RESULTED IN CARDIAC TRANSPLANTATION. Russian Journal of Cardiology, 2017, , 9-16.	1.4	13

#	Article	IF	CITATIONS
55	CARDIOVASCULAR DISEASES REGISTRY (RECVAZA): DIAGNOSTICS, CONCOMITANT CARDIOVASCULAR PATHOLOGY, COMORBIDITIES AND TREATMENT IN THE REAL OUTPATIENT-POLYCLINIC PRACTICE. Cardiovascular Therapy and Prevention (Russian Federation), 2015, 13, 44.	1.4	13
56	The prevalence of clinical factors used for risk assessment of osteoporotic fractures. Profilakticheskaya Meditsina, 2016, 19, 32.	0.6	13
57	OUTPATIENT REGISTER OF CARDIOVASCULAR DISEASES IN THE RYAZAN REGION (RECVASA): PRINCIPAL TASKS, EXPERIENCE OF DEVELOPMENT AND FIRST RESULTS. Rational Pharmacotherapy in Cardiology, 2013, 9, 4-14.	0.8	12
58	Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology, 2019, , 83-91.	1.4	12
59	Gut microbiota and vascular biomarkers in patients without clinical cardiovascular diseases. Artery Research, 2017, 18, 41.	0.6	11
60	HYPERTENSION IN THE ROUTINE HEALTHCARE: FOCUS ON THE RESULTS OF HEALTH CHECK-UP. Arterial Hypertension (Russian Federation), 2017, 23, 6-16.	0.4	11
61	HEART RATE AND ITS ASSOCIATION WITH THE MAIN RISK FACTORS IN THE POPULATION OF MEN AND WOMEN OF WORKING AGE. Rational Pharmacotherapy in Cardiology, 2017, 13, 819-826.	0.8	10
62	PRESCRIPTION OF MEDICATIONS INFLUENCING PROGNOSIS IN ATRIAL FIBRILLATION WITH ARTERIAL HYPERTENSION, CORONARY HEART DISEASE, CHRONIC HEART FAILURE, BY THE REGISTRY REKVAZA-CLINIC. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 33-38.	1.4	10
63	Atherosclerotic plaque in carotid arteries as a risk marker for cardiovascular events risk in middle aged population. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 34-39.	1.4	10
64	Contribution of four groups of noncommunicable diseases to mortality in the Russian Federation in 2015. Profilakticheskaya Meditsina, 2018, 21, 32.	0.6	10
65	Clinical-Epidemiological Program of Studying Psychosocial Risk Factors in Cardiological Practice in Patients With Arterial Hypertension and Ischemic Heart Disease: First Results of a Multicenter Study in Russia. Kardiologiya, 2018, 17, 47-58.	0.7	10
66	Prehypertension and cardiometabolic risk factors (data of the ESSE-RF study). Arterial Hypertension (Russian Federation), 2017, 23, 243-252.	0.4	10
67	The prevalence of abdominal obesity and the association with socioeconomic status in Regions of the Russian Federation, the results of the epidemiological study – ESSE-RF. Terapevticheskii Arkhiv, 2018, 90, 14-22.	0.8	10
68	Simulating the Impact of Improved Cardiovascular Risk Interventions on Clinical and Economic Outcomes in Russia. PLoS ONE, 2014, 9, e103280.	2.5	9
69	Optimal Medical Treatment versus Carotid Endarterectomy: The Rationale and Design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) Study. International Journal of Stroke, 2015, 10, 269-274.	5.9	9
70	PATIENTS WITH ATRIAL FIBRILLATION IN MULTIDISCIPLINARY HOSPITAL: STRUCTURE OF HOSPITALIZATION, CONCOMITANT CARDIOVASCULAR DISEASES AND DRUG TREATMENT (DATA OF RECVASA AF-TULA REGISTRY). Rational Pharmacotherapy in Cardiology, 2017, 13, 495-505.	0.8	9
71	Multiple rare and common variants in APOB gene locus associated with oxidatively modified low-density lipoprotein levels. PLoS ONE, 2019, 14, e0217620.	2.5	9
72	STATISTICAL, CLINICAL AND MORPHOLOGICAL CLASSIFICATIONS OF CORONARY HEART DISEASE — POSSIBLE TO UNITE?. Russian Journal of Cardiology, 2017, , 63-71.	1.4	9

#	Article	IF	Citations
73	ARTERIAL HYPERTENSION MANAGEMENT IN PATIENTS AGED OLDER THAN 80 YEARS AND PATIENTS WITH THE SENILE ASTHENIA. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 8-21.	1.4	9
74	Ischemic Heart Disease in Subjects of Young Age: Current State of the Problem: Prevalence and Cardio-Vascular Risk Factors. Kardiologiya, 2018, 17, 53-58.	0.7	9
75	Russian Medical Society for Arterial Hypertension Expert Consensus: Hypertension and COVID-19. Systemic Hypertension, 2020, 17, 35-41.	0.6	9
76	Factors Associated with Anxiety and Depressive Symptoms in 2775 Patients with Arterial Hypertension and Coronary Heart Disease: Results from the COMETA Multicenter Study. Global Heart, 2021, 16, 73.	2.3	9
77	PATIENTS WITH COMBINATION OF CHRONIC HEART FAILURE, HYPERTENSION AND HISTORY OF MYOCARDIAL INFARCTION: CLINICAL AND ANAMNESTIC CHARACTERISTICS, ADMINISTRATION OF ACE INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, -BLOCKERS AND ADHERENCE TO THE DRUG THERAPY (DATA OF) Tj ETQq1	10.78431	4 °rgBT /O∨
78	THE CONTROL OF INTERNATIONAL NORMALISED RATIO IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH WARFARIN IN OUTPATIENT AND HOSPITAL SETTINGS: DATA FROM RECVASA REGISTRIES. Rational Pharmacotherapy in Cardiology, 2018, 14, 40-46.	0.8	8
79	AN INTEGRATIVE BOIMARKER: OPPORTUNITIES FOR NON-INVASIVE DIAGNOSTICS OF CORONARY ATHEROSCLEROSIS. Russian Journal of Cardiology, 2017, , 132-138.	1.4	8
80	REDUCING MORTALITY FROM CARDIOVASCULAR AND OTHER NON-COMMUNICABLE DISEASES IN ECONOMIES WITH HIGH PER CAPITA INCOME: THE ACTIVITY OF NOT GOVERNMENT INSTITUTIONS. Cardiovascular Therapy and Prevention (Russian Federation), 2015, 14, 5.	1.4	8
81	AGE-RELATED CHANGES IN HEART RATE VARIABILITY AND THEIR RELATION WITH LEUCOCYTE TELOMERE LENGTH. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 54-60.	1.4	8
82	PSYCHOSOCIAL FACTORS AND LIFE QUALITY IN CORONARY HEART DISEASE PATIENTS: RESULTS OF THE RUSSIAN PART OF INTERNATIONAL MULTICENTER STUDY EUROASPIRE IV. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 20-26.	1.4	8
83	COMPLAINTS ON SLEEP BREATHING DISORDER AND CARDIOVASCULAR RISK FACTORS IN RUSSIAN REGIONS: DATA FROM ESSE-RF STUDY. Russian Journal of Cardiology, 2018, , 152-158.	1.4	8
84	Variable impedance cardiography waveforms: how to evaluate the preejection period more accurately. Journal of Physics: Conference Series, 2012, 407, 012016.	0.4	7
85	FEATURES OF SEASONAL CARDIOVASCULAR MORTALITY IN WINTER IN RUSSIAN REGIONS WITH DIFFERENT CLIMATIC AND GEOGRAPHICAL CHARACTERISTICS. Rational Pharmacotherapy in Cardiology, 2013, 9, 627-632.	0.8	7
86	THE PREVALENCE OF ELECTROCARDIOGRAPHIC INDICATORS AMONG MEN AND WOMEN OF OLDER AGES IN THE RUSSIAN FEDERATION. Rational Pharmacotherapy in Cardiology, 2016, 12, 711-717.	0.8	7
87	COMBINED ANTIHYPERTENSIVE THERAPY IN REAL CLINICAL PRACTICE. FOCUS ON FIXED COMBINATIONS OF ANTIHYPERTENSIVE DRUGS (According to the Data of Outpatient Registries RECVASA and PROFILE). Rational Pharmacotherapy in Cardiology, 2017, 13, 323-329.	0.8	7
88	Familial left ventricular noncompaction: phenotypes and clinical course. Results of the multicenter registry. Terapevticheskii Arkhiv, 2021, 93, 381-388.	0.8	7
89	The Double Mutation DSG2-p.S363X and TBX20-p.D278X Is Associated with Left Ventricular Non-Compaction Cardiomyopathy: Case Report. International Journal of Molecular Sciences, 2021, 22, 6775.	4.1	7
90	Hyperuricemia versus lifestyle in men and women of the Russian Federation population. Russian Open Medical Journal, 2020, 9, .	0.3	7

#	Article	IF	Citations
91	ULTRASOUND MARKERS OF PREMANIFEST ATHEROSCLEROSIS OF CAROTID AND FEMORAL ARTERIES IN ASSESSMENT OF CARDIOVASCULAR RISK. Russian Journal of Cardiology, 2018, , 92-98.	1.4	7
92	The impact of economic crisises on population health. Profilakticheskaya Meditsina, 2016, 19, 4.	0.6	7
93	Setting up a system for monitoring θ °nd evaluation of tobacco control measures aimed at protection from the environmental tobacco smoke θ °nd reduction of tobacco θ 3/4nsumption. Profilakticheskaya Meditsina, 2016, 19, 4.	0.6	7
94	PREVENTIONAL SCREENING: ALL PROS AND CONTRAS. Cardiovascular Therapy and Prevention (Russian) Tj ETQqC	0 0 0 rgBT 1.4	/9verlock 10
95	CHARACTERISTICS OF PATIENTS WITH CEREBRAL STROKE OR TRANSIENT ISCHEMIC ATTACK, INCLUDED INTO THE LIS-2 REGISTER (LYUBERTSY STUDY OF MORTALITY IN PATIENTS AFTER STROKE). Rational Pharmacotherapy in Cardiology, 2015, 11, 18-24.	0.8	6
96	CORRELATIONS OF DIFFERENT STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF ARTERIAL WALL WITH TRADITIONAL CARDIOVASCULAR RISK FACTORS IN HEALTHY PEOPLE OF DIFFERENT AGE. PART 2. Rational Pharmacotherapy in Cardiology, 2016, 12, 244-252.	0.8	6
97	Association of renal function, telomere length, and markers of chronic inflammation in patients without chronic kidney and cardiovascular diseases. Advances in Gerontology, 2016, 6, 217-223.	0.4	6
98	ORAL ANTICOAGULANTS IN AMBULATORY AND IN-HOSPITAL TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION ASSOCIATED WITH HYPERTENSION, ISCHEMIC HEART DISEASE AND CHRONIC HEART FAILURE: DATA FROM HOSPITAL REGISTRY RECVASA-CLINIC. Rational Pharmacotherapy in Cardiology, 2017, 13, 146-154.	0.8	6
99	Comparative Safety and Efficacy of Left Atrial Appendage Occlusion with the Watchman Device and Amplatzer Cardiac Plug: Results of the Russian National Registry. BioMed Research International, 2020, 2020, 1-7.	1.9	6
100	Effectiveness and Tolerability of the Single-Pill Combination of Bisoprolol and Perindopril in Patients with Arterial Hypertension and Stable Coronary Artery Disease in Daily Clinical Practice: The STYLE Study. Advances in Therapy, 2021, 38, 3299-3313.	2.9	6
101	Years of Life Lost Due to Premature Death and Their Relationship with Climate and Socio-Economic Performance of Regions. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2015, 70, 456-463.	0.6	6
102	DIABETES RISK AND ASSOCIATIONS WITH DEMOGRAPHIC AND BEHAVIORAL FACTORS IN RUSSIAN POPULATION: DATA FROM THE ESSE-RF STUDY. Russian Journal of Cardiology, 2017, , 13-20.	1.4	6
103	Telomere length and vascular wall in patients with Type 2 Diabetes Mellitus. Diabetes Mellitus, 2014, 17, 31-38.	1.9	6
104	SUBSEQUENT MYOCARDIAL INFARCTION: RISK ASSESSMENT AND PREVENTION. Russian Journal of Cardiology, 2017, , 139-145.	1.4	6
105	RELATION OF ANTHROPOMETRIC INDEXES AND CORONARY HEART DISEASE. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 11-16.	1.4	6
106	THE EFFECTIVENESS OF OUTPATIENT AND HOSPITAL LIPID-LOWERING THERAPY IN PATIENTS WITH HIGH AND VERY HIGH CARDIOVASCULAR RISK DURING 2011-2015. Rational Pharmacotherapy in Cardiology, 2016, 12, 622-630.	0.8	5
107	MODERN POSSIBILITIES OF ACHIEVING TARGET BLOOD PRESSURE LEVEL IN HYPERTENSIVE PATIENTS IN OUTPATIENT PRACTICE: THE LEADER STUDY RESULTS. Rational Pharmacotherapy in Cardiology, 2018, 14, 12-20.	0.8	5
108	Correction of Hypertriglyceridemia as the Way to Reduce Residual Risk in Diseases Caused by Atherosclerosis. Conclusion of the Advisory Board of the Russian Society of Cardiology, the Russian Scientific Medical Society of Therapists, the Eurasian Association of Therapists, the Russian National Atherosclerosis Society, the Russian Association of Endocrinologists, and the National League of Cardiologic Genetics. Rational Pharmacotherapy in Cardiology, 2019, 15, 282-288.	0.8	5

#	Article	IF	CITATIONS
109	THE SPECIFICS OF NONCOMPACTED CARDIOMYOPATHY MANIFESTATION. Cardiovascular Therapy and Prevention (Russian Federation), 2015, 14, 78.	1.4	5
110	Quality of lipid-lowering therapy in outpatient practice: RECVAS Register data. Profilakticheskaya Meditsina, 2016, 19, 9.	0.6	5
111	THE OUTPATIENT BASED REGISTRY RECVASA: PROSPECTIVE FOLLOW-UP DATA, RISK EVLUATION AND OUTCOMES IN CARDIOVASCULAR PATIENTS. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.7843	1144rgBT /	Oserlock 10
112	ORGANIZATIONAL ISSUES OF CARDIOREHABILITATION SERVICE IN RUSSIA. THE RESULTS OF PILOT PROJECT "DEVELOPMENT OF REHABILITATION SYSTEM OF CARDIOVASCULAR PATIENTS IN MEDICAL INSTITUTIONS OF RUSSIAN FEDERATION ENTITIES― Cardiovascular Therapy and Prevention (Russian Federation), 2016, 15, 4-12.	1.4	5
113	The issues of healthy lifestyle and prevention of non-communicable diseases in the Federal Law of the Russian Federation â€∞On Fundamental Healthcare Principles in the Russian Federation―under No. 323-FZ dated November 21, 2011: Analytical review and suggestions for changes and additions. Profilakticheskava Meditsina. 2016. 19. 10.	0.6	5
114	Early detection of alcohol users with hazardous consequences and their primary health care: A review of literature. Profilakticheskaya Meditsina, 2016, 19, 51.	0.6	5
115	Medical prophylactic examination of certain adult population groups from Russia as a tool for the early detection of malignant neoplasms (the 2015-2016 results). Profilakticheskaya Meditsina, 2018, 21, 13.	0.6	5
116	Chronic heart failure: evolution of etiology, prevalence and mortality over the past 20 years. Terapevticheskii Arkhiv, 2022, 94, 5-8.	0.8	5
117	Perspectives: Preventive measures for public health in Russian Federation. European Heart Journal Supplements, 2014, 16, A84-A86.	0.1	4
118	Fighting with obesity: the "gold standard" and new horizons. Rational Pharmacotherapy in Cardiology, 2016, 12, 450-458.	0.8	4
119	Mammographic Screening as a Tool for Cardiovascular Risk Assessing. Part 1. Breast Arterial Calcification: Pathomorphology, Prevalence and Risk Factors. Rational Pharmacotherapy in Cardiology, 2019, 15, 244-250.	0.8	4
120	Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases. Archives of Medical Science, 2021, , .	0.9	4
121	CARDIOMYOPATHY IN THE FRIEDREICH ATAXIA: CLINICAL PRESENTATION AND DIAGNOSTICS OF COMPLICATIONS. Russian Journal of Cardiology, 2017, , 100-106.	1.4	4
122	GUT MICROBIOTA AND ITS RELATIONS WITH CARDIOVASCULAR RISK FACTORS IN ALMOST HEALTHY INHABITANTS OF MOSCOW AND MOSCOW REGION. Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 ()104rgBT /	Overlock 10
123	Trends in simulated 10-year mortality rates and the evaluation of the socioeconomic efficiency of different scenarios of prevention. Profilakticheskaya Meditsina, 2016, 19, 12.	0.6	4
124	The modern integrated system for evaluating the effectiveness of research institutions subordinated to the Ministry of Health of Russia. Profilakticheskaya Meditsina, 2016, 19, 52.	0.6	4
125	A comparative analysis of mortality rates in Moscow and Saint Petersburg in 2015. Profilakticheskaya Meditsina, 2017, 20, 18.	0.6	4
126	Life quality of the Russian population by the data from ESSE-RF study. Cardiovascular Therapy and Prevention (Russian Federation), 2016, 15, 84-90.	1.4	4

#	Article	IF	CITATIONS
127	Comparison of myocardial infarction mortality rates in the regions of the Russian Federation in 2006 and 2015. Profilakticheskaya Meditsina, 2017, 20, 11.	0.6	4
128	THE INTERIM EXPERTS' COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES. Rational Pharmacotherapy in Cardiology, 2016, 12, 186-190.	0.8	3
129	TCT-825 Simplicity Denervation System for Pulmonary Artery Denervation in Patients with Chronic Thrombembolic Pulmonary Hypertension (first-in-man study). Journal of the American College of Cardiology, 2016, 68, B334.	2.8	3
130	Modern probabilistic and statistical approaches to search for nucleotide sequence options associated with integrated diseases. Russian Journal of Genetics, 2017, 53, 1091-1104.	0.6	3
131	Subfractional Spectrum of Serum Lipoproteins and Gut Microbiota Composition in Healthy Individuals. Microorganisms, 2021, 9, 1461.	3.6	3
132	Exposure of electronic cigarettes in Russia: results from Russian tobacco control policy evaluation study. , 2018, , .		3
133	THE INFLUENCE OF ECOLOGICAL RISK FACTORS ON MORTALITY IN MOSCOW POPULATION. RISK EVALUATION AND PREDICTION. Russian Journal of Cardiology, 2016, , 34-40.	1.4	3
134	Position Statement on Challenges in Assessing Cause-Specific Mortality. Kardiologiya, 2018, 17, 63-66.	0.7	3
135	ENDOTHELIAL GLYCOCALYX — POTENTIAL VASCULAR BIOMARKER: DIAGNOSTIC AND THERAPEUTIC TARGET IN CARDIOVASCULAR DISEASES. Cardiovascular Therapy and Prevention (Russian Federation), 2015, 14, 87.	1.4	3
136	SPECIFICS OF SUBFRACTIONAL SPECTRUM OF APOLIPOPROTEIN B RELATED LIPOPROTEINES IN CAROTID OR CORONARY ATHEROSCLEROSIS PATIENTS. Russian Journal of Cardiology, 2016, , 64-70.	1.4	3
137	Non-communicable diseases in Asia-Pacific Economic Cooperation member economies: Opportunities for achieving the sustainable development goals by 2030. Profilakticheskaya Meditsina, 2016, 19, 4.	0.6	3
138	The actual results of the work of health centers in Russia. Profilakticheskaya Meditsina, 2016, 19, 50.	0.6	3
139	RELATION OF CARDIOVASCULAR RISK FACTORS AND LEUKOCYTE TELOMERE LENGTH. Cardiovascular Therapy and Prevention (Russian Federation), 2016, 15, 52-57.	1.4	3
140	Relationship between socioeconomic factors and mortality rates in the population. Profilakticheskaya Meditsina, 2017, 20, 10.	0.6	3
141	ENDOVASCULAR TREATMENT OF THE RESIDUAL THROMBOEMBOLIC PULMONARY HYPERTENSION AFTER PULMONARY THROMBENDARTERECTOMY WITH THE DENERVATION SYSTEM SYMPLICITY. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 43-48.	1.4	3
142	ASSOCIATION OF MOLECULAR GENETIC FACTORS WITH THE SIGNS OF ATEROSCLEROTIC PLAQUES INSTABILITY. Russian Journal of Cardiology, 2018, , 32-38.	1.4	3
143	Regional challenges and opportunities in cardiovascular research: The Russian Federation "SWOT― analysis. American Heart Journal, 2011, 161, 427-430.	2.7	2
144	Determinants of mortality. Herald of the Russian Academy of Sciences, 2016, 86, 473-480.	0.6	2

#	Article	IF	CITATIONS
145	BLOOD PRESSURE PHENOTYPES IN TREATED HYPERTENSIVE PATIENTS IN SUMMER AND WINTER: FOCUS ON MASKED UNCONTROLLED HYPERTENSION. PART 1: BLOOD PRESSURE PHENOTYPES PREVALENCE. Rational Pharmacotherapy in Cardiology, 2017, 13, 578-589.	0.8	2
146	THE STUDY "REGISTER OF PATIENTS AFTER ACUTE STROKE (REGION)". PART 2. OUTPATIENT PROSPECTIVE REGISTER OF PATIENTS AFTER ACUTE STROKE (ACCORDING TO THE RESULTS OF THE PILOT PHASE OF THE) TJ E	TQq800	rg B T /Overloc
147	Chronic Heart Failure in Rheumatoid Arthritis Patients (Part II): Difficulties of Diagnosis. Rational Pharmacotherapy in Cardiology, 2019, 14, 870-878.	0.8	2
148	Mobile application "Aterostop―for a comprehensive assessment of cardiovascular risk in patients in the Russian population. Terapevticheskii Arkhiv, 2021, 93, 415-420.	0.8	2
149	Expert council resolution on regional program of early T2D detection, prevention and treatment in Russian Federation. Diabetes Mellitus, 2017, 20, 233-237.	1.9	2
150	LIPID PROFILE AND GENETIC MARKERS ASSOCIATED WITH THE LEVEL OF OXIDIZED LOW DENSITY LIPOPROTEIDES. Russian Journal of Cardiology, 2017, , 49-54.	1.4	2
151	DO FATS OR CARBOHYDRATES SHORTEN OUR LIVES? WHAT DOES THE PURE STUDY REVEAL?. Russian Journal of Cardiology, 2018, , 202-206.	1.4	2
152	DYNAMICS IN MEDICAL TREATMENT OF ISCHEMIC HEART DISEASE IN CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2013, 9, 611-618.	0.8	2
153	T-Cadherin and the Ratio of Its Ligands as Predictors of Carotid Atherosclerosis: A Pilot Study. Biomedicines, 2021, 9, 1398.	3.2	2
154	NON-COMPACTION MYOCARDIUM OF THE LEFT VENTRICLE: SECONDARY PREVENTION OF THROMBOEMBOLISM. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 100-104.	1.4	2
155	What "new―factors should be considered when assessing cardiovascular risk?. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 77-85.	1.4	2
156	Combination of Atrial Fibrillation and Coronary Heart Disease in Patients in Clinical Practice: Comorbidities, Pharmacotherapy and Outcomes (Data from the REĐ¡VASA Registries). Rational Pharmacotherapy in Cardiology, 2021, 17, 702-711.	0.8	2
157	Markers of vascular damage depending on the blood pressure level: data of the population study ESSE-RF. Russian Journal of Cardiology, 2020, 25, 3652.	1.4	2
158	Losses related to premature death at an economically active age. Herald of the Russian Academy of Sciences, 2015, 85, 510-514.	0.6	1
159	The implementation of health care aimed at the cessation of tobacco use, treatment of tobacco dependence and consequences of tobacco consumption in the Russian Federation. Rational Pharmacotherapy in Cardiology, 2016, 12, 403-413.	0.8	1
160	Endothelium Protective Function of Statins in Men and Women with Coronary Atherosclerosis. Rational Pharmacotherapy in Cardiology, 2016, 12, 503-508.	0.8	1
161	THE ASSOCIATION OF DEPRESSION WITH C-REACTIVE PROTEIN (THE DATA OF ESSE-RF EPIDEMIOLOGICAL) TJ E	TQg110.	784314 rgET
162	The prevalence of heterozygous familial hypercholesterolemia in the Russian Federation: A substudy of the ESSE-Rf. Atherosclerosis, 2017, 263, e184-e185.	0.8	1

#	Article	IF	Citations
163	Achievement of LDL-C goals in patients at moderate to very high cardiovascular risk on lipid-lowering drug therapy (cepheus II). Atherosclerosis, 2017, 263, e236-e237.	0.8	1
164	HEALTHCARE RESOURCES UTILIZATION AND TEMPORARY DISABILITY IN POPULATION AGED 50-64 ACCORDING TO THE EPIDEMIOLOGICAL ESSE-RF STUDY. Rational Pharmacotherapy in Cardiology, 2017, 13, 432-442.	0.8	1
165	BLOOD PRESSURE PHENOTYPES IN TREATED HYPERTENSIVE PATIENTS IN SUMMER AND WINTER: FOCUS ON MASKED UNCONTROLLED HYPERTENSION. Part 2. The main markers. Rational Pharmacotherapy in Cardiology, 2017, 13, 736-745.	0.8	1
166	Basic Anthropometric Indices and Diabetes Mellitus Type 2 in Russian Population. Rational Pharmacotherapy in Cardiology, 2018, 14, 725-732.	0.8	1
167	To lower trans fatty acid intake as an important condition for the reduction of cardiovascular mortality. Profilakticheskaya Meditsina, 2017, 20, 4.	0.6	1
168	The seasonal variability of blood pressure in outpatients without arterial hypertension diagnosis. The high prevalence of the isolated increase of ambulatory blood pressure. Profilakticheskaya Meditsina, 2017, 20, 21.	0.6	1
169	Seasonal changes in blood pressure parameters in hypertensive patients in two regions of the Russian Federation: results of additional data analysis. Profilakticheskaya Meditsina, 2018, 21, 70.	0.6	1
170	GUT ENTEROBIOTA — A NEW PLAYER IN ATHEROSCLEROSIS PATHOGENESIS. Cardiovascular Therapy and Prevention (Russian Federation), 2014, 13, 56-61.	1.4	1
171	SUBFRACTIONAL SPECTRUM OF HIGH DENSITY LIPOPROTEIDS IN CORONARY ATHEROSCLEROSIS PATIENTS. Cardiovascular Therapy and Prevention (Russian Federation), 2015, 14, 31-34.	1.4	1
172	AGE-RELATED LEFT VENTRICLE MYOCARDIAL REMODELING: IS THERE A LINK WITH NORMAL AGEING?. Cardiovascular Therapy and Prevention (Russian Federation), 2015, 14, 52-57.	1.4	1
173	THE REVIEW OF RUSSIAN PUBLICATIONS DURING THE YEARS 2010-2014. THE USE OF SCOPUS DATABASE FOR THE EVALUATION SPEED INTEGRATING INTO WORLDWIDE SCIENTIFIC SOCIETY. Cardiovascular Therapy and Prevention (Russian Federation), 2015, 14, 66.	1.4	1
174	GUT MICROBIOTA AND CARDIOVASCULAR RISK FACTORS. PART III. LIPID PROFILE, CARBOHYDRATE METABOLISM AND GUT MICROBIOTA. Cardiovascular Therapy and Prevention (Russian Federation), 2015, 14, 83.	1.4	1
175	Identification of chronic respiratory diseases and their risk factors during health survey of the adult population: Methodological aspects. Profilakticheskaya Meditsina, 2016, 19, 21.	0.6	1
176	Gut microbiota and cardiovascular risk factors. Part IV. Arterial hypertension, smoking and the gut microbiota. Cardiovascular Therapy and Prevention (Russian Federation), 2016, 15, 69-72.	1.4	1
177	Cardiovascular risk factors in hypothyroidism in the populations of the Russian Federation and the USA. Profilakticheskaya Meditsina, 2016, 19, 19.	0.6	1
178	Detection of malignant tumors of the breast and female reproductive organs during medical prophylactic examination of certain adult population groups. Profilakticheskaya Meditsina, 2016, 19, 4.	0.6	1
179	Telomere length, telomerase activity and mechanisms change in patients with type 2 diabetes mellitus. Problemy Endokrinologii, 2016, 62, 16-24.	0.8	1
180	Potential marker of endothelial dysfunction in patients with various grade of cardiovascular risk. Cardiovascular Therapy and Prevention (Russian Federation), 2016, 15, 57-62.	1.4	1

#	Article	IF	CITATIONS
181	Sleep duration and cardiovascular risk: results of the large-scale epidemiology study ESSE-RF. Arterial Hypertension, 2019, 23, 248-255.	0.3	1
182	Lipoprotein Profile in Populations from Regions of the Russian Federation: ESSE-RF Study. International Journal of Environmental Research and Public Health, 2022, 19, 931.	2.6	1
183	CORRELATIONS OF DIFFERENT STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF ARTERIAL WALL WITH TRADITIONAL CARDIOVASCULAR RISK FACTORS IN HEALTHY PEOPLE OF DIFFERENT AGE. PART 1. Rational Pharmacotherapy in Cardiology, 2016, 12, 118-128.	0.8	0
184	Integrated biomarker and short-term survival in patients with coronary atherosclerosis. Atherosclerosis, 2017, 263, e194-e195.	0.8	0
185	Prescription patterns of lipid-lowering therapy in patients with cardiovascular disease and hypertriglyceridemia in real clinical practice in Russia. Atherosclerosis, 2017, 263, e237.	0.8	0
186	Rare mutations in the APOB gene and its role in LDL oxidation. Atherosclerosis, 2017, 263, e81-e82.	0.8	0
187	Novel integrated biomarker for coronary atherosclerosis prediction. Atherosclerosis, 2017, 263, e194.	0.8	0
188	Genetics of familial hypercholesterolemia in patients recruited from epidemiological study. Atherosclerosis, 2017, 263, e281.	0.8	0
189	DRUG TREATMENT OF PATIENTS WITH THE HISTORY OF ACUTE STROKE: DATA OF THE PILOT PHASE OF THE OUTPATIENT REGISTRY «REGION». Rational Pharmacotherapy in Cardiology, 2017, 13, 346-356.	0.8	0
190	Differences between the Mortality Rates of Moscow and St. Petersburg. Herald of the Russian Academy of Sciences, 2018, 88, 127-132.	0.6	0
191	Pages of the History of Russian Medicine: Academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor Alexey Petrovich Golikov – Doctor, Scientist, Citizen (to the 100th) Tj ETQq1 1 0.	7843 8 4 rg	gBT¢Overlock
192	Comparison of efficacy of different long-acting nitrates drug compounds in patients with stable angina. Cardiovascular Therapy and Prevention (Russian Federation), 2014, , 52-57.	1.4	0
193	MORBIDITY AND MORTALITY FROM CARDIOVASCULAR DISEASES ACCORDING TO THE SEA-LEVEL RELATED ALTITUDE OF A REGION. Cardiovascular Therapy and Prevention (Russian Federation), 2014, 13, 51-55.	1.4	0
194	GUT MICROBIOTA AND CARDIOVASCULAR RISK FACTORS. PART 2. GUT MICROBIOTA AND OBESITY. Cardiovascular Therapy and Prevention (Russian Federation), 2015, 14, 83.	1.4	0
195	CURRENT ISSUES OF OBESITY CLASSIFICATION. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.	784314 rg 1.4	BT/Overlock
196	GUT MICROBIOTA AND CARDIOVASCULAR RISK FACTORS. PART 1. GUT MICROBIOTA, AGE AND SEX. Cardiovascular Therapy and Prevention (Russian Federation), 2015, 14, 92.	1.4	0
197	THE STUDY OF LONGEVITY: RECENT UPDATES AND FURTHER DIRECTION. PART 2. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 133-138.	1.4	0
198	THE STUDY OF LONGEVITY: RECENT UPDATES AND FURTHER DIRECTION. PART 1. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 75-80.	1.4	0

#	Article	IF	CITATIONS
199	THE ROLE OF GLYCEMIA VARIABILITY IN THE PROCESSES OF CELLULAR AND VASCULAR AGEING IN PATIENTS WITH TYPE 2 DIABETES. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 39-45.	1.4	O
200	New opportunities in the early identification of people at high risk for stroke at mass preventive medical examinations. Profilakticheskaya Meditsina, 2018, 21, 130.	0.6	0
201	Electronic nicotine delivery systems - new challenge for tobacco control policy: results from Russian tobacco control policy evaluation study. , 2018, , .		O
202	Annual influenza vaccination of patients with cardiovascular diseases and changes in hemagglutinin antibody titers: 3-year follow-up data. Epidemiology and Infectious Diseases (Russian Journal), 2020, 25, 88-101.	0.1	0
203	Remote Screening for Atrial Fibrillation by a Federal Cardiac Monitoring System in Primary Care Patients in Russia: Results from the Prospective Interventional Multicenter FECAS-AFS Study. Global Heart, 2022, 17, 4.	2.3	0